Jane Street’s Apogee Therapeutics APGE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.56M Sell
26,800
-5,200
-16% -$468K ﹤0.01% 4227
2026
Q1
$2.69M Buy
32,000
+25,600
+400% +$1.86M ﹤0.01% 4542
2025
Q4
$483K Buy
6,400
+1,200
+23% +$75.6K ﹤0.01% 7760
2025
Q3
$207K Sell
5,200
-2,200
-30% -$84K ﹤0.01% 9619
2025
Q2
$321K Buy
+7,400
New +$282K ﹤0.01% 7730
2025
Q1
Sell
-7,600
Closed -$344K 9361
2024
Q4
$344K Buy
+7,600
New +$388K ﹤0.01% 7508

Other funds holding APGE

Jane Street's APGE Position: Q2 2026 in Review

Jane Street opened a new position in Apogee Therapeutics (APGE) in Q2 2026: 3,245 shares worth $431K. The stake represents ﹤0.01% of the portfolio and ranks #8381 among its holdings. This is a return to the name: Jane Street previously reported a position in APGE as recently as Q4 2025.

Jane Street first reported a position in APGE in Q3 2023 and has held it in 11 quarters since. The position peaked at $3.73M in Q1 2024. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Jane Street held 3,245 shares of Apogee Therapeutics worth $431K as of Q2 2026.
  • Apogee Therapeutics was a new Jane Street position in Q2 2026.
  • Apogee Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #8381 holding.
  • Jane Street first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • Jane Street's Apogee Therapeutics position peaked at $3.73M in Q1 2024.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.